Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3551 to 3600 of 4090 results for patient

  1. Breast cancer (HER2-negative, BRCA-mutation, unresectable) - niraparib [ID1084]

    Discontinued Reference number: GID-TA11178

    Technology appraisal guidance
    Discontinued

  2. Non-invasive skin closure devices for surgical incisions (MT775)

    In development Reference number: GID-MT593 Expected publication date: TBC

    Medical technologies guidance
    In development

  3. Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]

    In development Reference number: GID-TA11511 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]

    In development Reference number: GID-TA11692 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]

    In development Reference number: GID-TA11750 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]

    In development Reference number: GID-TA11092 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [TSID12099]

    In development Reference number: GID-TA11640 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Pegcetacoplan for amyotrophic lateral sclerosis [TSID10594]

    In development Reference number: GID-TA11310 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. 500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause

    A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy (HRT) is not suitable.

    News
    Last updated
    27 March 2026

  10. Prostate cancer (hormone relapsed, metastatic) - rilimogene galvacirepvec (with rilimogene glafolivec, chemotherapy-naive) [ID1018]

    Discontinued Reference number: GID-TA11177

    Technology appraisal guidance
    Discontinued

  11. Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]

    In development Reference number: GID-TA11697 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]

    Discontinued Reference number: GID-TA11399

    Technology appraisal guidance
    Discontinued

  13. Sacubitril valsartan for treating chronic heart failure with preserved ejection fraction [ID1606]

    Discontinued Reference number: GID-TA11257

    Technology appraisal guidance
    Discontinued

  14. Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]

    Discontinued Reference number: GID-TA11339

    Technology appraisal guidance
    Discontinued

  15. Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]

    In development Reference number: GID-TA11627 Expected publication date: TBC

    Technology appraisal guidance
    In development

  16. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]

    Discontinued Reference number: GID-TA11338

    Technology appraisal guidance
    Discontinued

  17. Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke [TSID11920]

    In development Reference number: GID-TA11482 Expected publication date: TBC

    Technology appraisal guidance
    In development

  18. QTUG for assessing falls risk and frailty (MIB73)

    NICE has developed a medtech innovation briefing (MIB) on the Quantitative Timed Up and Go (QTUG)

    Medtech innovation briefing
    Published
    26 July 2016

  19. Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]

    In development Reference number: GID-TA11272 Expected publication date: TBC

    Technology appraisal guidance
    In development

  20. Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071]

    In development Reference number: GID-TA11634 Expected publication date: TBC

    Technology appraisal guidance
    In development

  21. Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]

    In development Reference number: GID-TA11327 Expected publication date: TBC

    Technology appraisal guidance
    In development

  22. OrganOx metra for liver transplant [ID5116]

    Discontinued Reference number: GID-TA11035

    Technology appraisal guidance
    Discontinued

  23. Bimekizumab for treating ankylosing spondylitis ID4011

    Discontinued Reference number: GID-TA11171

    Technology appraisal guidance
    Discontinued

  24. Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [TSID12194]

    In development Reference number: GID-TA11771 Expected publication date: TBC

    Technology appraisal guidance
    In development

  25. Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [TSID12203]

    In development Reference number: GID-TA11781 Expected publication date: TBC

    Technology appraisal guidance
    In development

  26. Rolofylline for the treatment of acute heart failure [ID96]

    Discontinued Reference number: GID-TA11258

    Technology appraisal guidance
    Discontinued

  27. Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]

    In development Reference number: GID-TA11848 Expected publication date: TBC

    Technology appraisal guidance
    In development

  28. Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]

    In development Reference number: GID-TA11709 Expected publication date: TBC

    Technology appraisal guidance
    In development

  29. Nivolumab with ipilimumab for untreated PD-L1 positive unresectable or metastatic urothelial cancer [ID3829]

    Discontinued Reference number: GID-TA10707

    Technology appraisal guidance
    Discontinued

  30. Capecitabine for the treatment of advanced pancreatic cancer [ID127]

    Discontinued Reference number: GID-TA11239

    Technology appraisal guidance
    Discontinued

  31. Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021]

    In development Reference number: GID-TA11556 Expected publication date: TBC

    Technology appraisal guidance
    In development

  32. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]

    Discontinued Reference number: GID-TA11318

    Technology appraisal guidance
    Discontinued

  33. Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]

    In development Reference number: GID-TA11365 Expected publication date: TBC

    Technology appraisal guidance
    In development

  34. Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]

    In development Reference number: GID-TA11831 Expected publication date: TBC

    Technology appraisal guidance
    In development

  35. Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]

    Discontinued Reference number: GID-TA11302

    Technology appraisal guidance
    Discontinued

  36. Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]

    In development Reference number: GID-TA11274 Expected publication date: TBC

    Technology appraisal guidance
    In development

  37. Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]

    Discontinued Reference number: GID-TA11343

    Technology appraisal guidance
    Discontinued

  38. Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]

    In development Reference number: GID-TA11273 Expected publication date: TBC

    Technology appraisal guidance
    In development

  39. Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]

    In development Reference number: GID-TA11402 Expected publication date: TBC

    Technology appraisal guidance
    In development

  40. Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer [TSID12065]

    In development Reference number: GID-TA11588 Expected publication date: TBC

    Technology appraisal guidance
    In development

  41. Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468]

    In development Reference number: GID-TA11581 Expected publication date: TBC

    Technology appraisal guidance
    In development

  42. Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]

    In development Reference number: GID-TA11301 Expected publication date: TBC

    Technology appraisal guidance
    In development

  43. Cendakimab for treating eosinophilic oesophagitis in people 12 years TS ID 12088

    Discontinued Reference number: GID-TA11702

    Technology appraisal guidance
    Discontinued

  44. Pazopanib for adjuvant treatment of locally advanced renal cell carcinoma [ID1091]

    Discontinued Reference number: GID-TA11240

    Technology appraisal guidance
    Discontinued

  45. Masitinib for treating relapsed or refractory peripheral T-cell non-Hodgkin lymphoma [ID1125]

    Discontinued Reference number: GID-TA11173

    Technology appraisal guidance
    Discontinued

  46. Secukinumab for treating giant cell arteritis in people 50 years and over [ID6563]

    In development Reference number: GID-TA11761 Expected publication date: TBC

    Technology appraisal guidance
    In development

  47. Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]

    Discontinued Reference number: GID-TA11261

    Technology appraisal guidance
    Discontinued

  48. Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]

    Discontinued Reference number: GID-TA10637

    Technology appraisal guidance
    Discontinued

  49. Bimekizumab for treating active non-radiographic axial spondyloarthritis [ID4010]

    Discontinued Reference number: GID-TA11151

    Technology appraisal guidance
    Discontinued

  50. Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab [ID1487]

    Discontinued Reference number: GID-TA10437

    Technology appraisal guidance
    Discontinued